Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Expansion from CHECKMATE-032; nivolumab and ipilimumab for metastatic urothelial carcinoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.10.18
Views: 391

Dr Jonathan E. Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA

Dr Jonathan E. Rosenberg talks to ecancer at ESMO 2018 about the CHECKMATE-032 trial looking at nivolumab with ipilimumab for patients with metastatic urothelial carcinoma.

After giving the latest data from the study, Dr Rosenberg provides his opinions and also the future direction for patients with metastatic urothelial carcinoma, given these outcomes.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation